Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240)
Fast, easy summary view of NICE guidance on 'colorectal cancer'
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
This appraisal relates to the treatment of wild-type KRAS metastatic colorectal cancer for first-line treatment in combination with FOLFOX, and for second-line treatment in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: colorectal cancer
This page was last updated: 25 March 2014
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.